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social and logistic conditions. The latter are based on opinion and
depend on local conditions. Analysis of the literature showed that
patients hospitalized with suspected pulmonary TB should be put in
precautionary respiratory isolation regardless of their age while they
await diagnosis. The general conditions for re-admission into the
community are at least 14 days of effective treatment and negative
microscopic tests of 3 consecutive samples in previously microscopi-
cally positive patients.
This is the first paper that provides indications to hospitalization of
children with TB. Most recommendations are generally applicable in
all developed countries. Some might need an adaptation to local
setting, epidemiological, parameters, and availability of specific
health-care facilities.
(Medicine 94(50):e2045)
Abbreviations: EPTB = extrapulmonary TB, MDR = multi-drug
resistant, MTB = meningeal tuberculosis, OR = odds ratio, RR =
relative risk, SITIP = Italian Society of Pediatric Infectious
Diseases, TB = tuberculosis, WHO = World Health Organization,
XDR = extensively drug-resistant.
INTRODUCTION
T uberculosis (TB) is the second most frequent infectiouscause of death after HIV infection worldwide.1 The latest
World Health Organization (WHO) report estimates that, in
2012, there were 8.6 million incident cases of TB worldwide
(the equivalent of 122 cases per 100,000 inhabitants) and 1.3
million TB-related deaths (including 940,000 HIV-negative and
320,000 HIV-positive subjects).1 The massive immigration
rates from endemic areas toward developed countries contrib-
utes to TB spreading and triggered a major interest in the
management of patients who have developed any of the stages
of the infection. Children with peculiar clinical manifestations
often require a specific expertise. However, any global strategy
for TB control must also take into account measures to address
the social and environmental issues that are inextricably linked
with TB.2
The management of TB is based on a probabilistic
approach in which the clinical history, the exposure to contacts,
selected host-related underlying conditions, and the clinical
features are evaluated in order to define the infection state
and to search for signs and symptoms of active TB disese. These
are then used for medical decision and management, including
treatment, hospitalization, re-admission in community, and
follow-up. However, in recent years a progressively increasing
number of cases come from at risk countries with refugees and
immigrants. It is estimated that in the year 2014 170,000 to
200,000 refugees arrived in Italy, and then reached other
European countries, after crossing the Mediterranean sea.
Often, in this population, previous clinical history or infor-
mation on exposure is not available. In addition, the incidence
of risk factors such as malnutrition or coinfection with HIV is
relatively common. The social conditions, the language and
other cultural barriers add to the problem of management of this
fragile population and hamper the probabilistic approach to TB.
Another issue is the lack of information on previous TB
immunization that raises problems in the interpretation of skin
test. Specific interferon gamma tests may be used to diagnose
infection and discriminate this from immunization, although
Vecchio et althey are not fully validated in infants and young children.
TB has multiple implications and should be managed
based on clinical consideration but also taking into account
2 | www.md-journal.compublic health as well as social and logistical aspects and
obviously human rights and ethical issues. In line with this
vision, very recently the Global TB Programme of the WHO
recommended to address the vulnerable and hard-to-reach
groups and to specifically address special needs of migrants
and cross-border issues as a priority to limit the infection
spreading and move toward TB elimination in low-incidence
countries.3
This paper was prepared in the light of the challenges
linked to this evolving scenario of TB in children. There is no
reference paper or guidelines to indicate hospitalization and
pediatricians need to move with no specific protocols. To cover
this gap, the Italian Society of Pediatric Infectious Diseases
(SITIP) coordinated a panel of expert from several scientific
societies with the aim of producing a paper with the indications
to hospital admission of children with possible or defined TB.
Isolation measures, hospital discharge, and readmission into the
community were also revised based on available data and
indications from health institutions and organisms. This docu-
ment describes the recommendations derived from the con-
sensus made by the group of experts.
METHODS
Using the Consensus Conference method described in the
National Institutes of Health Guidelines and the Italian National
Guidelines Programme,4,5 relevant publications in English were
identified by systematically reviewing MEDLINE and the
Cochrane Database of Systematic Reviews from their inception
until 31 December 2014. The key search words were: children[-
Title/Abstract] OR pediatric[Title/Abstract] OR paediatric[Title/
Abstract] AND tuberculosis[Title/Abstract] AND Hospital[Title/
Abstract] OR Hospitalization[Title/Abstract] OR Admission[Ti-
tle/Abstract] OR Re-admission[Title/Abstract] OR Isolation
[Title/Abstract] OR Length of stay[Title/Abstract] OR Compli-
cations[Title/Abstract] OR Referral[Title/Abstract] OR Consul-
tation[Title/Abstract] OR Medical visit [Title/Abstract] AND
English[lang], and the Working Group agreed on a list of clinical
problems related to pediatric hospitalization due to TB and TB
management. The evidence review focused on patients in the age
group 0 to 18 years and included section-specific targeted
searches and formal systematic reviews of selected items. In
addition, the clinical recommendations made in the updated,
relevant international guidelines were reviewed and critically
compared. All data were entered in tables of evidence for each
item and extensively discussed.
Trained investigators critically appraised the available data
using the Scottish Intercollegiate Guidelines Network meth-
odological checklists (Table 1)6 and, subsequently, the biblio-
graphical material and a preliminary draft of the document were
provided to the panel members. During meetings, the published
evidence was presented and discussed, and the Delphi method
was used to reach a consensus when the evidence did not
provide consistent and unambiguous recommendations.6 The
final text was revised on the basis of these discussions and
submitted by e-mail to the participants at the Consensus Con-
ference for final approval. According to the Italian National
Guidelines Programme,4 only publications approved by the
Ethics Committee of the authors can be included in a systematic
review, but it is not requested that the authors of a systematic
review have to request the approval from their Ethics Commit-
Medicine  Volume 94, Number 50, December 2015tee for the analysis of the literature and the preparation of a
guideline or a Consensus document. The members of the
multidisciplinary panel of clinicians and experts in evidence-
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Quality of Evidence and Strength of Recommendation
Quality of evidence
I Evidence from >1 properly designed, randomized,
controlled study, and/or systematic review of
randomized studies
II Evidence from 1 properly designed, randomized,
controlled study
III Evidence from cohort studies or their meta-analysis
IV Evidence from retrospective case-controlled studies
or their meta-analysis
V Evidence from case series without control group
VI Evidence from opinions of respected authorities,
based on clinical experience
Strength of recommendation
A The panel strongly supports a recommendation for
use
B The panel moderately supports a recommendation for
use
Medicine  Volume 94, Number 50, December 2015based medicine were indicated by the national scientific
societies, and included experts in the fields of general pediatrics,
pediatric infectious diseases, neonatology, infectious diseases,
C The panel marginally supports a recommendation for
usepneumology, microbiology, radiology, public health, pharma-
cology, and methodologists; the panel was coordinated by the
SITIP. No panel member declared conflict of interest. The panel
TABLE 2. Risk Factors for Severe Course, Complication or Death
Host-Related
Factors Risk
Child age
< 1 year Risk of death
Risk of severe outcome, EPTB, military
Risk of developing neurological sequelae d
< 3 years Risk of miliary TB
Risk of developing neurological sequelae d
< 5 years Risk of developing neurological sequelae d
Underlying conditions
HIV infection Risk of death
Risk of death for class C according to C
Risk of death for those with no improvement a
Risk of miliary TB
Risk of developing neurological sequelae d
Malnutrition Risk of persistent positive sp
Risk of treatment failur
Risk of death
Risk of clinical or radiologic worsening after 10
Risk of death in children with HIV infecti
Solid organ or bone
marrow transplantation
Risk of TB and possible disseminatio
Clinical feature
EPTB Risk of severe outcomes, death, and tr
Meningeal TB Risk of death
Glasgow Coma Scale
< 11
Risk of death
Risk of neurological seque
Multidrug resistant TB Risk of death
CDC¼Centers for Disease Control and Prevention, CI¼ confidence inte
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.met on 3 occasions, but many of the consultations involved in
developing the document took place interactively by e-mail
or telephone.
RESULTS
Indications to Hospital Admission of a Child With
Suspected or Diagnosed TB
The indications to hospitalization of children with sus-
pected or confirmed TB are largely indirect and based on
observational studies. Even the latest international guidelines
do not provide recommendations based on data.7,8
The suspicion and/or diagnosis of TB and treatment are not
per se indications to hospitalization.9 The hospitalization of
patients with suspected TB should be based on 3 sets of criteria:
(1) host-related conditions, (2) clinical criteria (eg, severity,
suspected, or proved drug resistance), and (3) social and logistic
criteria (eg, homeless, people living with immunocompromised
subjects, and community residents).7,8
As specific indications to hospital admission are not
available and comparative studies are unethical, the panel
extrapolated potential indications to hospital management iden-
tifying those conditions at higher risk of severe disease course
or death.
Child age and the presence of underlying conditions may
require hospital management (Table 2). According to available
evidence, children aged< 1 year have a significantly higher risk
Hospitalization and Isolation of Children With TBof severe outcomes and a greater frequency of extrapulmonary,
miliary, and disseminated TB and demonstrated a higher risk of
death compared to older children.10–12
in Children With Tuberculosis (TB)
Estimated Risk
(95%CI) References
OR 2.06 (1.18–3.57) 8
, and meningitis  8, 9, 10
uring meningeal TB RR 2.9 23
19
uring meningeal TB RR 3.0 23
uring meningeal TB RR 1.9 23
OR 24.7 (1.79–341.1) 11
DC classification RR 2.4 22
fter 6 months of therapy RR 3.7 22
OR 10.9 (XX) 20
uring meningeal TB RR 2.3 23
utum OR 3.71 (1.22–11.3) 11
e OR 3.21 (1.15–8.96) 11
OR 9.56 (1.79–51.2) 11
days after therapy onset OR 3.45 (1.1–10.0) 12
on and malnutrition RR 2.6 22
n with EPTB OR 40–50 24
eatment failure  8, 11
OR 3.22 (1.09–9.52) 10
OR 11.7 (3.10–53.2) 11
lae OR 3.8 (1.45–9.94) 11
OR 63.9 (4.84–843.2) 11
rval, EPTB¼ extrapulmonary TB, TB¼ tuberculosis.
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Irrespective of age, patients with HIV are at high risk of a
poor outcome.10,13 Excluding the studies characterized by
multiple confounding factors, HIV has been found to be an
independent risk factor that increases the risk of death in
children with TB by up to 24 times13 (Table 2). Although this
is probably associated only with severe immune deficiency,
hospitalization is indicated for any child with HIV/TB coin-
fection at least at the initial diagnosis.
Other chronic conditions may be associated with a risk of
complications and severe course of TB.Malnutrition (defined as
a weight below the third percentile) is associated with a greater
risk of persistently positive expectorate, failure to respond to
antitubercular therapy and death.13 A Canadian study found that
low-weight children (<25th percentile) were at greater risk of
clinical and/or radiographic worsening of existing lesions or the
development of new lesions associated with clinical/radio-
graphic changes occurring 10 or more days after the onset of
antitubercular treatment and after documented initial clinical
response (Table 2).
In addition to host-related factors, the decision to hospi-
talize a child with suspected or diagnosed TB should be guided
by clinical factors14 (Table 2).
As pulmonary TB is still the most frequent clinical feature
in children, the clinical indications to hospitalization of patients
with nonspecific community-acquired pneumonia can be
applied for children with pulmonary TB.15–17 Accordingly,
children with respiratory distress and/or blood oxygen satur-
ation levels of< 92% should be hospitalized because of the
greater risk of severe complications.15–17
Extrapulmonary TB (EPTB) accounts for 20% of the
cases of pediatric TB and is characterized by increased severity
and a worse clinical course including death or a failure to
respond to treatment.10,13 Meningeal TB (MTB) is a cause of
death or neurologic permanent sequelae: children with MTB are
3 times more likely to die than those with other forms of TB.12
Furthermore, patients with Glasgow Coma Scale scores of< 11
and those requiring ventriculo-peritoneal shunt are at high risk
of death.13 Considering the risk of complications, children
presenting with EPTB and MTB should be referred to hospital
(Table 2).
Finally, both pulmonary and extrapulmonary forms of TB
that are resistant to first-line drugs lead to management diffi-
culties, and may therefore require hospitalization at least during
the early phases of diagnosis and treatment. One study carried
out in South Africa found a markedly increased risk of death in
children with TB caused by multidrug resistant (MDR)
strains.13
In addition, there are specific diagnostic (ie gastric aspira-
Vecchio et altion) and therapeutic (ie intravenous treatment) procedures that
cannot be instituted at home or in an outpatient setting and
therefore require hospitalization.18
Referral to a Tertiary Care Center of Children at
Risk of Developing Complicated TB
The management of children with suspected or diagnosed
TB should generally be entrusted to healthcare personnel with
specific training and experience in pediatric TB.
In addition, there are particular conditions associated with
a high risk of complicated TB that strongly require the highly
specialized management such as that provided by a pediatric TB
reference centre.
Observational data showed that some condtions are related
with a high risk of miliary TB, complication, handicap, or
4 | www.md-journal.comneurological sequelae during MTB and hence should be man-
aged in referral centers.
Neonate and preschool children have a higher risk of
complications and should be managed in an age-specific appro-
priate setting. A meta-analysis of 170 newborns with congenital
TB derived from a large number of case series showed that
46.8% had a miliary form and 11.1% multiple pulmonary
nodules.19 The highest mortality rates were observed in patients
with intracranial lesions (65% vs 20.8%,P< 0.001) and in those
whose symptoms appeared before the third of week of life
(76.5% vs 52.2%, P¼ 0.004).
Age< 5 years has been identified as a risk factor for
miliary TB and MTB in 3 studies carried out in South Africa.
In the population studied byMarais et al the majority (84.2%) of
the children with these forms were< 3 years of age.20 Van den
Bos et al found that their patients with concomitant miliary TB
and MTB were significantly younger than those with MTB
alone (P¼ 0.04).21
Two South African prospective studies found that HIV-
infected children more frequently presented with complicated
and miliary forms of TB (odds ratio [OR] 10.9) and had a
consequently higher rate of mortality (P¼ 0.003).20,22 In those
children, the presence of CD4þ lymphocytes15% at the time
of the diagnosis was significantly associated with miliary TB
(P¼ 0.05).23 The advanced stage of HIV infection (clinical
category C: relative risk [RR] 2.4), considerable degree of
malnutrition (RR 2.6), and failure to respond after 6 months
of antitubercular therapy (RR 3.7) were all significantly associ-
ated with a high risk of mortality.24
Young age (0–1 year: RR 2.9, P< 0.001; 1–2 years: RR 3,
P< 0.001; 2–5 years RR 1.9, P¼ 0.03) and HIV infection (RR
2.3, P¼ 0.05) are also significantly associated with handicaps
or sequelae in children with proven or probable MTB, as
demonstrated in a retrospective study of 554 children.25
A similar risk of complication was found in children with
African ethnicity (P¼ 0.008), disease stage (P< 0.001), the
presence of brainstem dysfunction (P< 0.001), and the pre-
sence of an infarction revealed by a brain computed tomography
scan (P¼ 0.001) in multivariate analysis.25
It is likely that patients with congenital immunodeficien-
cies and those treated with immunosuppressants or immuno-
modulating biological drugs also have a greater tendency to
develop EPTB, but the data are largely limited to single cases or
small series. However, 1 large-scale Spanish study of children
who underwent solid organ or bone marrow transplantation
Medicine  Volume 94, Number 50, December 2015showed 40- to 50-fold increased incidence of TB compared to
general pediatric population, with a prevalence of disseminated
forms during the first post-transplant year.26
Indications to Isolation of Children With
Suspected or Diagnosed TB
Hospitalized patients with suspected pulmonary TB should
be admitted into preventive respiratory isolation regardless of
their age while they await diagnosis.27,28 Pediatric patients are
often considered to be relatively noncontagious at least until
they reach adolescence. At this age the clinico-radiological
characteristics of pulmonary TB become similar to those
observed in adults consisting in a high incidence of cavitary
lesions that are associated with respiratory spreading of infec-
tion.29–31 Three studies performed in United States demon-
strated a complete lack of transmission from children with
typical pulmonary TB (ie, without the characteristics of
adult-type TB) to healthcare workers despite the occurrence
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
of uncontrolled exposure.32–34 However, anecdotal reports of trans-
mission (including in-hospital transmission) involving young
patients are available.35–39 Table 3 reports the hallmarks of potential
contagiousness in children with suspected or confirmed TB.
Respiratory isolation should be carried out by confining
the patient to a single-bedded hospital room identified by
clearcut signals including the date isolation onset.40 Isolation
in a negative-pressure chamber (that fulfills specific, legally
required technological specifications) should be considered for
suspected or proved MDR or extensively drug-resistant (XDR)
TB, and in suspected drug-sensitive TB if there are immuno-
compromised patients in the same ward.40
Patients in respiratory isolation must wear a specific
protective devices every time they leave their room, which
should only be allowed when it is medically necessary (eg, in
order to undergo diagnostic procedures).40 Healthcare staff and
visitors should adopt measures of individual protection.40 How-
ever, various studies (mainly carried out in the USA) reported a
suboptimal compliance with these indications, without any
substantial increase in nosocomial transmission.41–44
If patients do not require hospitalization for other reasons
and are at risk of spreading the infection, respiratory isolation
can be implemented at home provided that there is sufficient
family/social support and there are no risks for household
members or the community at large.40 However, this decision
needs to be carefully considered in each case.
Indications to Hospital Discharge and Re-
Admission to the Community
Discharge from hospital and readmission in the com-
munity are not only based on clinical criteria but also they
should take into account the risk of spreading the infection to
other subjects.
Data on discharge are very limited. Patients with gastric
aspiration/sputum-negative TB can be considered at no risk of
spreading the infectiion after 2 weeks of treatment (supported
by a negative result of cultured specimens). In contrast, sputum-
positive patients may be contagious for longer time45 and the
initial bacterial positivity and the presence of cavitary pulmon-
ary lesions predict a slower microbiological conversion.46,47
Observational data suggest that, in patients with bacilliferous
TB, culture tests of cough-produced aerosol became negative
within the third week of treatment.48,49 Ritchie et al suggest the
use of bacterial load as an indicator of the time necessary for the
negativization of culture: ie 7 days for patients with sputum
Medicine  Volume 94, Number 50, December 2015scores ofþ 1 andþ 2 (respectively 1–9 alcohol/acid-fast
bacilli/100 fields and 1–9 alcohol/acid-fast bacilli/10 fields),
14 days for those with a score ofþ 3 (1–9 alcohol/acid-fast
TABLE 3. Hallmarks of Potential Contagiousness
Indicators
Clinical Persistent productive cough Adolesce
bronchial TB Suspected drug-resistant T
invasive investigations of the
Radiological Excavated pulmonary lesions involveme
the inferior lob
Microbiological Microscopic positivity for acid/alcohol-fa
or broncho-alveolar la
TB¼ tuberculosis.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.bacilli/field), and 25 days for those with a score ofþ 4 (10 alco-
hol/acid-fast bacilli/field).50 However, molecular biology stu-
dies have demonstrated that a decrease in selected RNAs
sequences (antigen-alpha, antigen 85, isocitrate lyase) early
during therapy is a reliable measure of mycobacterial replica-
tion and viability that reflects the efficacy of treatment and
indicates noncontagiousness.51–54
Respiratory isolation (in hospital or at home) can be dis-
continued as soon as at least 3 samples of sputumhave been found
to bemicroscopically negative. Data collected in adults but not in
children suggest that 2 negative samples may be sufficient
because it is very unlikely that the third would be positive.55–57
The management of MDR cases deserves a specific con-
sideration, although it is not clearly addressed in available
guidelines. A study of a large patient cohort carried out in
South Africa reported repositivization of culture tests in 11.6%
and 5.4% of 336 adults with MDR TB 1 and 2 months after
conversion respectively, thus supporting the WHO’s indication
that treatment should monitored by at least 2 consecutive
negative tests after conversion with an interval of at least 30
days in subjects with MDR TB.1,58
The identificationofunequivocal criteria for allowingchildren
withTB to return to the community is basedoncommonsense anda
careful clinical assessment in order to guarantee safe and reasonably
rapid return to normal life without risks. Although they do not
always address the question specifically or exhaustively, the guide-
lines produced by leading international societies suggest that the
necessary conditions are 3 consecutive microscopically negative
sputum/gastric aspirate samples, clinical remission, and treatment
compliance.27 Furthermore, WHO recommends confirmation of
culture test conversion after 3 weeks,1 based on specific data.59 The
American Academy of Pediatrics indicates that pediatric patients
can be readmitted in the community and resume their normal
activities provided that treatment has been started, is regularly
taken, and has led to a clinical improvement.60
DISCUSSION
Summary of Evidence
The multidisciplinary panel, after reviewing and evaluat-
ing the data available for each clinical question, developed
clinical recommendations based on evidence and, when insuf-
ficient, on consensus of expert. Grading of evidence is reported
for each recommendation.
Hospitalization and Isolation of Children With TBHospitalization Criteria
As shown in Table 4, indications to hospital admission are
essentially based on 3 groups of criteria: (1) host-related
Supporting References
nce Suspected laryngeal/
B Congenital TB Need for
respiratory tree
30,31,39
nt of the apical segments of
es
27
st bacilli in a sputum sample
vage fluid
26
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ment does not require ordinary hospitalization (eg, in the
TABLE 4. Indications to Hospitalization in Children With Suspected or Diagnosed Tuberculosis (TB)
Criteria for Hospital Admission
Strongly
Recommended Grading

To be Considered
(but not Necessarily
Required) Grading

Age < 1 year V-B Severe malnutrition
(<3rd percentile)
III-A
Host-related conditions Chronic underlying disease and/or
exposed to a greater risk of severe
manifestations or disseminated TB
infection (eg chemotherapy)
III-A
Underlying T lymphocyte
immunodeficiency and/or defects in
phagocytic oxidase-reductase metabolism
(eg HIV, primary immunodeficiency)
III-A
Severe pulmonary symptoms (eg
respiratory insufficiency, respiratory
distress, oxygen saturation <92%,
hemoptysis)
III-A Drug-induced adverse events VI-B
Clinical features Neurological signs and symptoms
suggesting meningeal TB
III-A
EPTB (excluding isolated lymphnode TB) III-A
TB due to drug-resistant mycobacteria III-A Proved or suspected tubercular
disease due to resistant
mycobacteria
III-A
Social and logistic criteria Need for in-hospital medical interventions
(invasive diagnostic procedures)
V-A Poor compliance with
anti-tubercular therapy
VI-B
Need for respiratory isolation in a
negative-pressure chamber
VI-B Presence of socio-economic
risk factors
VI-B
crit
Vecchio et al Medicine  Volume 94, Number 50, December 2015conditions, (2) clinical features, and (3) social and logistic criteria.
According to these parameters, hospitalization should either be
‘‘strongly recommended’’ or it can be ‘‘considered although not
necessarily urgently required’’ by the physician (Table 4).
Children with TB may be managed in primary and second-
ary-care pediatric hospital units providing the structures fulfill
isolation criteria.These indicationsmay change according to each
country and the organization of health-care facilities. Children
whoare considered at risk of developing complicated formsofTB
should always be referred to a tertiary care center specialized in
the diagnosis and treatment of pediatric TB. Those include
children with the following characteristics: congenital TB, new-
born children of women with TB, age< 3 years, malnutrition,
HIV infection with low CD4þ cell count, underlying T lympho-
cyte immunodeficiency and/or defects in phagocytic oxidase-
reductasemetabolism, subjects in the first year after a solid organ
transplant or bone marrow transplantation with graft vs host
disease [V-B], MTB, and EPTB excluding isolated lymph node
TB [III-A] and subjects with proved or suspected tubercular
disease due to resistant mycobacteria [III-A].
Isolation Measures
All children hospitalized for suspected contagious TB
under preliminary observation should be put in preventive
EPTB¼ extrapulmonary TB, TB¼ tuberculosis.
Quality of evidence and strength of recommendation according torespiratory isolation (Table 5) (VI-A). Respiratory isolation
is also indicated in all children hospitalized with suspected
or proved drug-resistant TB (VI-A).
6 | www.md-journal.comThis should be carried out by confining the patient to a
single-bedded hospital room identified by clear signals that must
also indicate the date on which the isolation is started (VI-A).
Isolation in a negative-pressure chamber (that respects
specific, legally required technological equipment) should be
considered in the case of suspected or proved MDR or exten-
sively drug-resistant (XDR) TB, or in the case of suspected
drug-sensitive TB if there are immunocompromised patients in
the same ward (VI-A).
Patients in negative-pressure isolation should only be
allowed to leave the room wearing a protective device and
exclusively when it is medically necessary (eg, diagnostic
procedures) (VI-A). Healthcare staff and visitors should weare
individual protective devices (VI-A).
Respiratory isolation at home is recommended in cases of
suspected contagious TBwhose diagnostic/therapeutic manage-
eria reported in Table 1.presence of family/social conditions compatible with outpati-
ent/domiciliary management) (VI-A).
Discharge and Re-Admission to the Community
The decision to discharge a patient should be based on
careful clinical evaluation and on conditions of social/family
support, including full treatment compliance and the consider-
ation that there is no risk for household members or the
community at large (Table 6 A) (VI-A).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
(2)
TABLE 5. Isolation Measures for Children With Tuberculosis (TB)
Isolation Measures Indication

Home respiratory isolation Suspected contagious TB whose diagnostic/therapeutic management does not require
ordinary hospitalization (ie family/social conditions favouring outpatient/domiciliary
management)
Hospital respiratory isolation All hospitalized patients with suspected contagious TB under preliminary observation
suspected or ascertained drug-resistant TB
Negative pressure chamber Suspected or ascertained MDR or extensively drug-resistant (XDR) TB
Suspected drug-sensitive TB if there are immunocompromised patients in the same ward
rug
ns w
Medicine  Volume 94, Number 50, December 2015 Hospitalization and Isolation of Children With TBPotentially contagious patientswhoare treatment-compliant
and have appropriate family/social support can be discharged
after at least 2weeks of treatment has led to clinical improvement
even if microscopic examination of sputum/gastric aspirate
samples are not yet negative provided that conditions allow
the continuation of respiratory isolation at home (VI-A).
If respiratory isolation at home is not feasible, 3 consecu-
tive samples of gastric aspirate (2 in the case of induced
expectorate) negative for alcohol/acid-fast bacilli should be
obtained to decide discharge (VI-A).
If sputum/gastric aspirate samples are negative from the
onset, discharge can be considered after 7 to 14 days of regularly
taken treatment have led to a clinical improvement (VI-A).
Discharge can be decided in the case of treatment compliant,
asymptomatic/paucisymptomatic patients (VI-A).
MDR¼multi-drug resistant, TB¼ tuberculosis, XDR¼ extensively d
According to the available evidence in support, all recommendatioIn the case of proved drug-resistant TB, discharge can be
planned only after obtaining negative culture test results, eg
after a clinical improvement and 3 consecutive microscopically
TABLE 6. Summary of the Main Criteria for Hospital Discharge (A
Population
A)
Clinical Scenario Dischar
Smear-positive patients Two weeks of effective t
improvement and family/soc
requested in patients for wh
applicable or no
Smear-negative patients 7–14 days of effective therapy
Suspected or ascertained
drug-resistant TB
Conversion to negative of cul
along with clinical improvem
isolation in therap
B)
Clinical Scenario Com
Smear-positive patients Smea
impro
Smear-negative patients No <
Ascertained drug-resistant TB (MDR or XDR TB) Cu
impro
pati
MDR¼multi-drug resistant, TB¼ tuberculosis, XDR¼ extensively drug
Quality of evidence and strength of recommendation according to crit
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.negative expectorate/gastric aspirate samples (VI-A). Further-
more, it is necessary to assess the adequacy of domiciliary
-resistant.
ere graded VI-A (see Table 1).treatm(3)
) an
ge Cr
reatm
ial su
om d
t the
alon
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ent a
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ents u
-resist
eria reent including adherence (VI-A).
The general indications for readmission to the community
le 6B) are:(Tab
(1) no less than 14 days of regularly taken treatment have led
to a clinical improvement in the case of initially sputum-
negative patients (VI-A);
three consecutive microscopically negative sputum/gastric
aspirate samples in the case of patients who were
previously microscopically positive (if possible using
the same type of biological sample as that used for the first
microbiological test), together with a clear clinical
improvement (regression of the symptoms present at
onset) and compliance to treatment (VI-A);
in the case of MDR or XDR forms, community
readmission is only indicated after culture negativization
d Readmission to the Community (B) in the Pediatric TB
iteria Level of Evidence

ent along with clinical
pport smear conversion is
omiciliary isolation in not
rapy adherent
VI-A
g with clinical improvement VI-A
esults, or smear conversion
nd domiciliary respiratory
pliant patients
VI-A
ty Re-admission Criteria Level of Evidence

version along with clinical
nt and therapy compliance
VI-A
eks of effective treatment VI-A
conversion and clinical
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nder regular monitoring
VI-A
ant.
ported in Table 1.
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8 |hio et al(preferably confirmed by 2 consecutive samples with an
interval of 15–30 days between them) and on therapeutic
continuity/monitoring (VI-A).
LIMITATIONS
This paper has some limitations. First of all, supporting
evidence is limited and its quality varies for each recommen-
dation. Criteria for hospitalization and isolation are based on
strong evidence demonstrating that selected conditions are
associated with a higher risk of severe outcomes and death.
On the other hand, indications to discharge and re-admission
into community, whose principes include consideration of the
risk of contagiousness, mainly comes from data on adult
population and opinion of experts. However, all the indications
have been formulated on the best available data derived from a
rigorous systematic review of the literature and the recommen-
dations were discussed by a multidisciplinary panel of experts
including clinicians, radiologists, microbiologists, and public
health experts from different scientific societies.
CONCLUSIONS
This paper was produced with the aim of providing clin-
icians with indications to admission, isolation and discharge of
children with suspected or confirmed TB, as part of a global
guidelines document on management of TB in children.
Recommendations must take into account social and
logistical conditions as well as costs related to disease’s man-
agement together with the classical clinical parameters. Accord-
ing to the algorithm of TB, child contagiuosness, exposition to
contacts, presence of underlying risk factors and prevalence of
MDR are key elements for the management of children with TB.
Those elements are essential also to set up appropriate isolation
measures, hospitalize or readmit into the community subjects
who can potentially spread the infection.
However, the scenario of TB in developed countries is
rapidly changing due to the increasing migration fluxes from
countries where the infection is endemic. This paper was
discussed in the light of the challenges linked to the evolving
situation associated with problems in applying the available
algorithms for diagnosis and treatment of TB. In terms of
diagnosis, the interpretation of the skin tuberculin test should
take into account the risk of exposure, previous clinical history,
and immunization status. Those conditions are often poorly
known in at risk children coming from at risk areas.
The indications to hospital management and isolation
measures are particularly relevant in order to prevent spreading
of infection where information on the TB exposition and
contacts is not available, knowledge of host-related risk factors
is often limited and hampered by linguistic barriers, domiciliary
isolation, and follow-up are not feasible, and widespreding of
MDR TB is a true risk.
Starting from the need of guidelines addressing this topic,
our document is intended as a temptative reference paper and the
indications to hospital admission, isolation, and discharge of
children with TB need to be validated after implementation at
local level. Most recommendations developed by the multidisci-
plinary team are applicable in all developed areas, altough some
may need tailoring to local setting, epidemiological parameters,
and availability of health-care facilities. In order to adopt theabilisticmodel ofmanagement of TB to the present scenario,
lose collaboration between clinicians, public health
orities, and field-workers is all the more essential.
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